COVID-19, Patients With Cancer, Vaccine Reaction
Conditions
Brief summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a global pandemic since late 2019 that resulted in more than 360 million population infection. Patients with cancers may be at higher risk of infection and severity than those without cancer. Mass vaccination has been carried out, but reinfection and vaccine breakthrough cases still occur. Now, the prime-boost regimen was identified safe and efficient, but the reactogenicity and immunogenicity of prime-boost vaccine strategy in cancer patients were not known.
Detailed description
This study is a prospective, single-arm, open-label clinical trial. A total of 100 patients with different cancers including breast cancer, hepatocellular carcinoma, lung cancer, esophageal cancer, gastric cancer and colorectal cancer were included in this heterologous prime-boost vaccination study. All of the patients will further accept 12 months follow-up study after prime-boost vaccination. Safety, reactogenicity and immunogenicity of the prime-boost vaccination in those patients will be carefully recorded and detected.
Interventions
BIOLOGICALCoronavirus vaccination
Patients in this trial need to accept a prime-boost vaccination against SARS-CoV-2 after 6 to 8 months of the first vaccination
Sponsors
Beijing 302 Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age above 18 years. 2. Patients with diagnosed cancers including breast cancer, hepatocellular carcinoma, lung cancer, esophageal cancer, gastric cancer and colorectal cancer. 3. Patients who have received local or systemic anti-cancer therapies according to the treatment guidelines previously or currently, and have a stable condition with the ECOG score below 2. 4. The functions of multi-organs were normal or basically normal, and there are no contraindications for vaccination.
Exclusion criteria
1. Patients with acute attack of chronic diseases. 2. Patients have history of convulsion, epilepsy, encephalopathy and psychosis. Patients who are allergic to any component of the vaccine, or have a serious history of vaccine allergy. 3. Pregnant or lactating women. 4. Sufferring serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, and severe hypertension can not be well controlled by drugs. Patients have severe chronic diseases or diseases can not be controlled well during the progress, such as asthma, diabetes, thyroid disease, etc. Congenital or acquired angioedema / neuroedema. 5. Systemic cytotoxic drugs, cell therapies including NK cells, cytokine induced killer cells, Dendritic cells, CTL and stem cells infusion are required during vaccination.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of adverse effects after prime-boost vaccination | Within 1 week after the prime-boost vaccination | Safety of the prime-boost vaccine |
| Titers of anti-SARS-CoV-2 antibodies | Within 3 months after the prime-boost vaccination | Immunogenicity of prime-boost vaccine |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Occurence of adverse effects after prime-boost vaccination | Within 1 month after the prime-boost vaccination | Safety of the prime-boost vaccine |
| Titers of anti-SARS-CoV-2 antibodies | Within 12 months after the prime-boost vaccination | Immunogenicity of prime-boost vaccine |
Countries
China
Contacts
Primary ContactFu-Sheng Wang, MD
Backup ContactRuonan Xu, MD
Outcome results
None listed